Expired activity
Please go to the PowerPak
homepage and select a course.
Updates in Glucagon-like Peptide-1 Receptor Agonist Use for Patients with Type 2 Diabetes to Maximize Glycemic and Non-glycemic Outcomes
This educational activity is sponsored by Postgraduate Healthcare Education, LLC (PHE) and supported by an educational grant from Novo Nordisk, Inc
Registration & Dates for Webinar
Wed, Apr 19, 2023
1:00 PM EDT
Faculty
Joshua J. Neumiller, PharmD, CDCES, FADCES, FASCP
Vice Chair & Allen I. White Distinguished Professor
Department of Pharmacotherapy, College of Pharmacy and Pharmaceutical Sciences
Washington State University
Spokane, WA
Jennifer Trujillo, PharmD, FCCP, BCPS, CDCES, BC-ADM
Professor, Department of Clinical Pharmacy
Skaggs School of Pharmacy and Pharmaceutical Sciences
University of Colorado Anschutz Medical Campus
Aurora, CO
Clinical Pharmacist and Certified Diabetes Care and Education Specialist
UCHealth Diabetes and Endocrinology Clinic
Anschutz Medical Campus
Aurora, CO
FINANCIAL DISCLOSURE
Dr. Neumiller has disclosed that he has served as a consultant for Bayer, Novo Nordisk, Inc. and Sanofi, and has received fees for non-CE services from Dexcom.
Dr. Trujillo has disclosed that she has served as a consultant for Sanofi and Novo Nordisk, Inc.
Susanne Batesko, RN, BSN, Robin Soboti, RPh, and Susan R. Grady, MSN, RN, as well as the planners, managers, and other individuals, not previously disclosed, who are in a position to control the content of Postgraduate Healthcare Education (PHE) continuing education (CE) activities hereby state that they have no relevant conflicts of interest and no financial relationships or relationships to products or devices during the past 12 months to disclose in relation to this activity. PHE is committed to providing participants with a quality learning experience and to improve clinical outcomes without promoting the financial interests of a proprietary business.
All relevant financial relationships have been mitigated.
ACCREDITATION STATEMENTS
PHARMACY
Postgraduate Healthcare Education, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
UAN: 0430-0000-23-006-L01-P
Credits: 0.5 hour (0.05 ceu)
Data/Time: Wednesday, April 19, 2023
1:00 – 1:30 PM ET
Type of Activity: Knowledge
Fee Information:There is no fee for this educational activity.
Estimated time to complete activity: 30 minutes
TARGET AUDIENCE
This accredited activity has been designed for pharmacists.
How to Earn Credit
Participants must 1) read the learning objectives and faculty disclosures; 2) attend and participate in the live webinar; and 3) complete the evaluation form directly after the event with a maximum of within 60 days of attending the live session. To answer the questions, click on your selected choice for each answer then proceed to the next question. Your credit will automatically uploaded to CPE Monitor.
GOAL
The goal of this PowerUp Live Q&A session is to provide learners the opportunity to ask the faculty questions about the use of GLP-1 Receptor Agonists (RAs) to improve glycemic and non-glycemic outcomes for patients with Type 2 diabetes.
For a more in-depth review of this topic, we recommend that you view the faculty’s CE monograph titled, Updates in Glucagon-like Peptide-1 Receptor Agonist Use for Patients with Type 2 Diabetes to Maximize Glycemic and Non-glycemic Outcomes (Part 1 of a 2-part series), available at https://www.powerpak.com/course/preamble/123192, (expires October 26, 2023)
EDUCATIONAL OBJECTIVES
Upon completion of this program, participants should be better able to:
- Discuss recent clinical trial data regarding GLP-1 RA use in patients with type 2 diabetes for both glycemic and non-glycemic outcomes
- Explain updated guideline recommendations regarding the use of GLP-1 RAs in patients with type 2 diabetes and appropriate candidate selection based on patient specific factors
REQUIRED COMPUTER HARDWARE/SOFTWARE
Please ensure the computer system you plan to use meets the following minimum requirements:
- Operating System: Windows 98 or higher & Macintosh 2.2 or higher
- Internet Browser (Mac &/ Windows): Internet Explorer 6.0 or higher, Google Chrome, Safari 5.0.6 or higher, Firefox 3.0.3 or higher & Opera 5 or higher
- Broadband Internet connection: Cable, High-speed DSL & any other medium that is internet accessible
- Peripherals: Computer speakers or headphones
- Monitor Screen Resolution: 320 x 480 or higher
- Media Viewing Requirements: Adobe Reader, Microsoft PowerPoint, Flash Player & HTML5
Disclosure of Unlabeled Use and Disclaimer
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Postgraduate Healthcare Education, LLC, or Novo Nordisk, Inc.. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions, and possible contraindications on dangers in use, (review of any applicable manufacturer's product information) and comparison with recommendations of other authorities.
The author, sponsor, and publisher of this continuing education activity have made all reasonable efforts to ensure that all information contained herein is accurate in accordance with the latest available scientific knowledge at the time of acceptance for publication. However, because information regarding drugs (their administration, dosages, contraindications, adverse reactions, interactions, special warnings, precautions, etc.) is subject to constant change, the reader is advised to check the manufacturer's package insert for information concerning recommended dosages and potential problems and cautions prior to dispensing or administering the drug. Special precautions should be taken when a drug is new, or highly toxic, or is unfamiliar to the dispenser or administrant. This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the U.S. Food and Drug Administration
(FDA). Neither the publisher nor sponsor promotes the use of any agent outside of approved labeling. Statements made in this monograph have not been evaluated by the FDA.
